Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PFE (Pfizer) How high will it go? -- Ignore unavailable to you. Want to Upgrade?

To: Mkilloran who wrote (7524)	4/26/1999 8:08:00 PM
From: BigKNY3	Read Replies (1) \| Respond to of 9523

Mkilloran <<may be the article in the NY Times today on Vivus patent for Female Sexual disfunction.>> Mk: I disagree. Any competitive activity in this market segment should have no impact on PFE. Most PFE analysts do not include a future Female Sexual Dysfunction indication in their sales forecasts. A major problem in this area is the lack of standards and difficulty in evaluating efficacy. If Viagra does receive a FSD indication, it would have a positive effect. The converse is not true. Here are some links relevant to your post concerning FDS and Viagra: archive.abcnews.go.com abcnews.go.com cnn.com msnbc.com msnbc.com BigKNY3